Our Compounding Laboratory in Kuala Lumpur

Every compounded preparation at Lynnity is formulated in our GCP-compliant laboratory in Kuala Lumpur, operated under the Poisons Act 1952 and Good Compounding Practice (GCP) 2018 by a registered pharmacist and a multidisciplinary scientific team.

Who operates the lab

• Vitthia Rama Murti, BPharm Hons (University of Cyberjaya), Pharmacy Board of Malaysia RPh 15632 — Registered Pharmacist & Compounding Director. Verifies every compounded prescription, signs off on dispensing, and oversees clinical governance.
• Amylia Syuhada, BSc Biomolecular Science (UiTM) — Head of Quality & Compliance. Oversees laboratory operations, inventory, supply chain, and internal audit.
• Ng Peng Wah, BSc Biotechnology (INTI) — Pharmaceutical Compounding Supervisor. Manages lab operations and leads liposomal & herbosomal formulation.
• Nur Sarah, BSc Applied Chemistry (IIUM) — Compounding Support Specialist. Assists in formulation, quality assurance, and documentation.
• Muhammad Anwar Izat, Diploma of Medical Science (UniMAIWP) — Facility & Instrumentation Technician. Maintains and calibrates all laboratory equipment.

Standards we work to

• Poisons Act 1952 (Malaysia) — primary legal framework for compounding.
• Good Compounding Practice (GCP) 2018, Pharmaceutical Services Programme, Ministry of Health Malaysia.
• USP <795> — non-sterile compounding standards.
• USP <797> — sterile compounding standards (where applicable).
• Raw materials sourced from FDA-registered international suppliers, screened against USP / BP / JP pharmacopoeial specifications.

Our quality-control workflow

1. Raw-material screening. Each incoming batch is checked against its Certificate of Analysis and verified by our QC team for identity, potency, and contaminant profile.
2. Formulation under controlled conditions. Temperature, humidity, and particulate counts are monitored during compounding.
3. Two-pharmacist verification. Every prescription is independently double-checked before dispensing — formulation against prescription, label against patient.
4. Random third-party potency testing. Sample batches are sent to accredited independent laboratories on a rolling basis for potency and microbial-limit confirmation.
5. Beyond-use-date (BUD) assignment. Each compound is dispensed with a USP-compliant BUD based on formulation type and any in-house stability data we hold.
6. Batch-record retention. Full compounding logs are retained for traceability, including pharmacist sign-off, ingredient lot numbers, and dispense details.

Liposomal & herbosomal process

Our liposomal encapsulation process uses pharmaceutical-grade phosphatidylcholine derived from non-GMO sunflower or soy lecithin. Active ingredients (vitamin C, glutathione, CoQ10, curcumin, etc.) are hydrated with the phospholipid phase, then size-reduced via sonication or microfluidisation to a target vesicle range of 100–250 nm. Every batch is checked for particle-size distribution, zeta potential, encapsulation efficiency, and microbial limits before release. See our liposomal technology page for the underlying science.

Visit or schedule a lab tour

Lynnity Compounding Pharmacy
5 & 5-1, Jalan 2/33B, MWE Commercial Park, Off Jalan Kepong, 52000 Kuala Lumpur, Malaysia
Open Monday to Friday, 8:30 AM – 6:00 PM.
Prescribers and clinic partners can arrange a guided tour by emailing info@lynnitypharma.com or WhatsApp +60 12-661 8987.